21 research outputs found
Getting shot of elves: healing, witchcraft and fairies in the Scottish witchcraft trials
This paper re-examines the evidence of the Scottish witchcraft trials for beliefs associated by scholars with "elf-shot." Some supposed evidence for elf-shot is dismissed, but other material illuminates the interplay between illness, healing and fairy-lore in early modern Scotland, and the relationship of these beliefs to witchcraft itself
Development of a heptaplex PCR assay for identification of Staphylococcus aureus and CoNS with simultaneous detection of virulence and antibiotic resistance genes
Background
Staphylococcal toxicity and antibiotic resistance (STAAR) have been menacing public health. Although vancomycin-resistant Staphylococcus aureus (VRSA) is currently not as widespread as methicillin-resistant S. aureus (MRSA), genome evolution of MRSA into VRSA, including strains engineered within the same patient under anti-staphylococcal therapy, may build up to future public health concern. To further complicate diagnosis, infection control and anti-microbial chemotherapy, non-sterile sites such as the nares and the skin could contain both S. aureus and coagulase-negative staphylococci (CoNS), either of which could harbour mecA the gene driving staphylococcal methicillin-resistance and required for MRSA-VRSA evolution.
Results
A new heptaplex PCR assay has been developed which simultaneously detects seven markers for: i) eubacteria (16S rRNA), ii) Staphylococcus genus (tuf), iii) Staphylococcus aureus (spa), iv) CoNS (cns), v) Panton-Valentine leukocidin (pvl), vi) methicillin resistance (mecA), and vii) vancomycin resistance (vanA). Following successful validation using 255 reference bacterial strains, applicability to analyse clinical samples was evaluated by direct amplification in spiked blood cultures (n = 89) which returned 100 % specificity, negative and positive predictive values. The new assay has LoD of 1.0x103 CFU/mL for the 16S rRNA marker and 1.0x104 CFU/mL for six other markers and completes cycling in less than one hour.
Conclusion
The speed, sensitivity (100 %), NPV (100 %) and PPV (100 %) suggest the new heptaplex PCR assay could be easily integrated into a routine diagnostic microbiology workflow. Detection of the cns marker allows for unique identification of CoNS in mono-microbial and in poly-microbial samples containing mixtures of CoNS and S. aureus without recourse to the conventional elimination approach which is ambiguous. In addition to the SA-CoNS differential diagnostic essence of the new assay, inclusion of vanA primers will allow microbiology laboratories to stay ahead of the emerging MRSA-VRSA evolution. To the best of our knowledge, the new heptaplex PCR assay is the most multiplexed among similar PCR-based assays for simultaneous detection of STAAR
Engineering of the LukS-PV and LukF-PV subunits of Staphylococcus aureusPanton-Valentine leukocidin for Diagnostic and Therapeutic Applications
Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.
BACKGROUND: Remote ischaemic conditioning with transient ischaemia and reperfusion applied to the arm has been shown to reduce myocardial infarct size in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). We investigated whether remote ischaemic conditioning could reduce the incidence of cardiac death and hospitalisation for heart failure at 12 months. METHODS: We did an international investigator-initiated, prospective, single-blind, randomised controlled trial (CONDI-2/ERIC-PPCI) at 33 centres across the UK, Denmark, Spain, and Serbia. Patients (age >18 years) with suspected STEMI and who were eligible for PPCI were randomly allocated (1:1, stratified by centre with a permuted block method) to receive standard treatment (including a sham simulated remote ischaemic conditioning intervention at UK sites only) or remote ischaemic conditioning treatment (intermittent ischaemia and reperfusion applied to the arm through four cycles of 5-min inflation and 5-min deflation of an automated cuff device) before PPCI. Investigators responsible for data collection and outcome assessment were masked to treatment allocation. The primary combined endpoint was cardiac death or hospitalisation for heart failure at 12 months in the intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT02342522) and is completed. FINDINGS: Between Nov 6, 2013, and March 31, 2018, 5401 patients were randomly allocated to either the control group (n=2701) or the remote ischaemic conditioning group (n=2700). After exclusion of patients upon hospital arrival or loss to follow-up, 2569 patients in the control group and 2546 in the intervention group were included in the intention-to-treat analysis. At 12 months post-PPCI, the Kaplan-Meier-estimated frequencies of cardiac death or hospitalisation for heart failure (the primary endpoint) were 220 (8·6%) patients in the control group and 239 (9·4%) in the remote ischaemic conditioning group (hazard ratio 1·10 [95% CI 0·91-1·32], p=0·32 for intervention versus control). No important unexpected adverse events or side effects of remote ischaemic conditioning were observed. INTERPRETATION: Remote ischaemic conditioning does not improve clinical outcomes (cardiac death or hospitalisation for heart failure) at 12 months in patients with STEMI undergoing PPCI. FUNDING: British Heart Foundation, University College London Hospitals/University College London Biomedical Research Centre, Danish Innovation Foundation, Novo Nordisk Foundation, TrygFonden
Engineering of the LukS-PV and LukF-PV subunits of Staphylococcus aureus Panton-Valentine leukocidin for Diagnostic and Therapeutic Applications
Abstract
Background: Staphylococcus aureus produces several toxins, including Panton-Valentine leukocidin (PVL). The
involvement of PVL in primary skin infections, necrotizing pneumonia, musculoskeletal disorders, brain abscess, and
other diseases, some of which are life-threatening, has been reported. Following expert opinion, we aimed to
provide the tools for establishment of sequence-based diagnostics and therapeutics for those conditions. We
engineered the synergistic S and F (LukS-PV and LukF-PV respectively) pro-toxin subunits from Staphylococcus
aureus USA400 into separate expression E. coli BL21(DE3)-pLysS hosts.
Results: Following Nickel affinity chromatography (NAC), the F subunit came out without bands of impurity. The
S sub-unit did not come off very pure after NAC thus necessitating further purification by size exclusion and
ion-exchange chromatography. The purification plots showed that the BioLogic-LP and AKTA systems are reliable
for following the progress of the chromatographic purification in real-time. Computer predicted Mw for the
6His-LukF-PV and 6His-LukS-PV were 35645.41 Da and 33530.04 Da respectively, while the mass spectrometry results
were 35643.57 Da and 33528.34 Da respectively.
Conclusion: The BioLogic-LP and AKTA systems are commendable for reliability and user-friendliness. As a recent work
elsewhere also reported that a second round of chromatography was necessary to purify the S subunit after the first
attempt, we speculate that the S subunit might contain yet unidentified motif(s) requiring further treatment. The
purified S and F sub-units of PVL were supplied to the Nottingham Cancer Immunotherapy group who used them to
establish sequence-based monoclonal antibodies for diagnostic and therapeutic uses targeting PVL
“When a man hath a familiar style”: An Introduction to Authorship Studies in Early Modern Drama and Literature
Novel Series of Dihydropyridinone P2X7 Receptor Antagonists
Identification of singleton P2X7
inhibitor <b>1</b> from
HTS gave a pharmacophore that eventually turned into potential clinical
candidates <b>17</b> and <b>19</b>. During development,
a number of issues were successfully addressed, such as metabolic
stability, plasma stability, GSH adduct formation, and aniline mutagenicity.
Thus, careful modification of the molecule, such as conversion of
the 1,4-dihydropyridinone to the 1,2-dihydropyridinone system, proper
substitution at C-5″, and in some cases addition of fluorine
atoms to the aniline ring allowed for the identification of a novel
class of potent P2X7 inhibitors suitable for evaluating the role of
P2X7 in inflammatory, immune, neurologic, or musculoskeletal disorders
Novel Series of Dihydropyridinone P2X7 Receptor Antagonists
Identification of singleton P2X7
inhibitor <b>1</b> from
HTS gave a pharmacophore that eventually turned into potential clinical
candidates <b>17</b> and <b>19</b>. During development,
a number of issues were successfully addressed, such as metabolic
stability, plasma stability, GSH adduct formation, and aniline mutagenicity.
Thus, careful modification of the molecule, such as conversion of
the 1,4-dihydropyridinone to the 1,2-dihydropyridinone system, proper
substitution at C-5″, and in some cases addition of fluorine
atoms to the aniline ring allowed for the identification of a novel
class of potent P2X7 inhibitors suitable for evaluating the role of
P2X7 in inflammatory, immune, neurologic, or musculoskeletal disorders